Paul G Ambrose, Pharm.D., FIDSA

Paul G. Ambrose is President of the Institute for Clinical Pharmacodynamics (ICPD), Latham, New York, USA. He is also an Honorary Research Fellow in Infectious Diseases at the University of Oxford, Oxford, UK and Adjunct Associate Research Professor at the University at Buffalo, Buffalo, New York.

Dr. Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained though the use of non-clinical (in vitro and animal) PK-PD infection models may be leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities. ICPD has successfully utilized this approach for support of regulatory decision-making and as support for Clinical and Laboratory Standards Institute susceptibility breakpoint determinations.

Dr. Ambrose is a member of the working group on ‘Skin and Skin Structure Infection-Community-Acquired Pneumonia’ for The Biomarkers Consortium at the National Institutes of Health, Bethesda, Maryland, USA and is a member of the ‘ReAct: Action on Antibiotic Resistance’ Working Group in Uppsala, Sweden.

He is Editor of Antimicrobial Agents Chemotherapy and an Editorial Board Member of the Journal of Infectious Disease Pharmacotherapy. Dr. Ambrose is the author of over 105 peer-reviewed scientific publications and approximately 150 scientific abstracts. Dr. Ambrose has served as an Editor for four textbooks; most notably the 1st and 2nd Editions of Antimicrobial Pharmacodynamics in Theory and Clinical Practice.


Yehuda Carmeli, MD, MPH

Dr. Carmeli is the head of the National Institute for Antibiotic Resistance and Infection Control & the Division of Epidemiology, at the Tel Aviv Medical Center, and a professor in Medicine, Tel Aviv University, Israel.  He is also on the research staff at the Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Dr. Carmeli received his MD degree from Ben Gurion University, Israel and his MPH degree at Harvard School of Public Health. He served his residency at Hadassah Medical Center, Hebrew University, Jerusalem, and then served as a fellow in Medicine at Massachusetts General Hospital, Boston. Dr. Carmeli completed his fellowship in Infectious Diseases at Beth Israel Deaconess Medical Center. His research focuses on antibacterial agents and in particular on the epidemiology of resistance to antibiotics, mechanisms of resistance and spread and clinical research of antibacterials. Dr. Carmeli is the recipient of the Finland research award of the Massachusetts Infectious Disease Society, and the John T. Smith award on research of new quinolones, the ICAAC program award for Pathogenesis of Microbial Diseases, and the Society of healthcare epidemiology (SHEA) Mentor Award. Dr. Carmeli is the recipient of multiple research grants including FP6 and FP7 European commission grants. He is the author of over 200 research articles, and is on the editorial board of several major journals in infectious diseases and hospital epidemiology.


Thomas M File Jr., MD, MSc, MACP, FIDSA, FCCP

Dr Thomas File is Chair of the Infectious Disease Division at Summa Health System in Akron, Ohio, USA and Professor of Internal Medicine, Master Teacher, and Chair of the Infectious Disease Section at Northeast Ohio Medical University in Rootstown, Ohio. After graduating from medical school at the University of Michigan, Ann Arbor, in 1972, Dr File received his Master of Science in medical microbiology from Ohio State University in Columbus, in 1977, where he also completed his fellowship in infectious diseases.

Dr File is a Master of the American College of Physicians, a fellow and a past member of the Board of Directors of the Infectious Diseases Society of America (IDSA), and a fellow of the American College of Chest Physicians. He is President of the Board of Directors of the National Foundation for Infectious Diseases and is a member of many other professional societies, including the American Society for Microbiology, the American Thoracic Society (ATS) and the European Society of Clinical Microbiology and Infectious Diseases. He is  a previous Chairperson of the Standards and Practice Guidelines Committee of the IDSA and has also served as a member of the IDSA and ATS committees for guidelines on community-acquired pneumonia; and is a member of the IDSA guidelines panels for hospital-acquired pneumonia, influenza and sinusitis. He is a past-president of the Infectious Disease Society of Ohio, and of the Northeastern Ohio Task Force on AIDS.

Primary research interests that Dr File has pursued include community-acquired respiratory tract infections, immunizations in adults, bacterial resistance in respiratory infections, infections in patients with diabetes, soft tissue infections, and evaluation of new antimicrobial agents. He has had extensive experience in the development and implementation of randomized clinical trials for evaluation of new antimicrobials. A frequent lecturer both nationally and internationally, Dr File has published more than 250 articles, abstracts and textbook chapters, focusing on the diagnosis, etiology and treatment of infectious diseases, and in particular, respiratory tract infections. He co-authored File TM Jr. and Stevens DL Contemporary Diagnosis and Management of Skin and Soft Tissue Infections,3rd Ed (2011, published by Handbooks in Health Care Co.) and co-edited Tan JS, File TM Jr., Salata RA, Tan MJ (eds.) Expert Guide to Infectious Diseases, 2nd edition (2008, published by ACP Press, Phil.). In addition, he is Editor-in-Chief of Infectious Diseases in Clinical Practice.


David Livermore, PhD

Professor of Medical Microbiology, University of East Anglia
David Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997 when he joined the Health Protection Agency (now Public health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In October 2011 he became Professor of Medical Microbiology at the University of East Anglia but with 30% of this time supplied back to Public Health England as its Lead on Antibiotic Resistance.

He has broad interests on the evolution and dissemination of antibiotic resistance and its relationship to antibiotic prescribing. β-Lactamases are a particular interest, with recent work on the proliferation of ‘CTX-M’ extended-spectrum enzymes and carbapenemases, particularly NDM-1, which received extensive media coverage in 2010.

Prof Livermore sits on the British Society for Antimicrobial Chemotherapy’s working parties on resistance surveillance, multi-resistant pathogens and susceptibility testing and its Antibiotic Action advisory board, also on the Society for General Microbiology’s working group on sexually transmitted infections. He also sits on the UK Government’s Antimicrobial Resistance and Healthcare Associated Infections Committee and contributed extensively to the English Chief Medical Officer’s Annual Report for 2012. He publishes and speaks widely on resistance and has edited for several journals including Journal of Antimicrobial Chemotherapy and Journal of Medical Microbiology and, currently, International Journal of Antimicrobial Agents.

Outside of work he is an inveterate walker of mountains and rugged coastlines.


Gianni Maria Rossolini, MD

Dr. Rossolini is a Full Professor of Microbiology and Clinical Microbiology, Universities of Florence and Siena, Italy. Dr. Rossolini is also a Director of the Clinical Microbiology and Virology Unit, Florence Careggi University Hospital and Member of the Board of Administrators, University of Siena. He has previously served as the Dean, Faculty of Medicine and President of the Medical School at University of Siena.

Dr. Rossolini is Chairman of the Antimicrobial study group of the Italian Society of Clinical Microbiologists. He has also served as Editor of Antimicrobial Agents and Chemotherapy since 2004 and served on the editorial board of several additional scientific journals (Journal of Antimicrobial Chemotherapy, BMC Microbiology, Future Microbiology, Journal of Chemotherapy, Microbial Drug Resistance).

Dr. Rossolini’s current fields of scientific interest: antimicrobial agents and antibiotic resistance mechanisms; surveillance, molecular epidemiology, and clinical impact of microbial drug resistance and nosocomial infections. He as authored more than 270 scientific articles listed in the PubMed database (total IF, 1152; h-index, 46) and is the inventor of seven patents.